drugset
drugset / Trial / NCT04313322

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

NCT04313322 ↗

Phase 1 Unknown 5 enrolled Stem Cells Arabia
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Timeline

Start
2020-03-16
Primary completion
2020-06-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject WJMSCs Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.